Table 1.

Patient characteristics by swab status

VariableNo Swaba (%), n=235PCR Negative (%), n=42PCR Negative/No Swab P ValuePCR Positive (%), n=79PCR Positive/No Swab P Value
Sex
 Women84 (35.7)20 (47.6)0.2726 (32.9)0.62
 Men151 (64.2)22 (52.3)53 (67.1)
Age (median), yr68 (54–73)62 (51–74)0.04c65 (54–73)0.69
Ethnicity
 Black29 (12.3)8 (19.0)0.499 (11.4)0.27
 White62 (26.4)9 (21.4)19 (24.1)
 Indoasian97 (41.2)19 (45.2)38 (48.1)
 Other47 (20.0)6 (14.2)13 (16.5)
Cause of ESKD
 APKD16 (6.8)1 (2.3)0.362 (2.5)0.43
 Diabetic nephropathy85 (36.1)17 (40.5)32 (40.5)
 GN43 (18.2)6 (14.2)12 (15.2)
 Other35 (14.9)9 (21.4)5 (6.3)
 Unknown47 (20.0)8 (19.0)25 (31.6)
 Urologic9 (3.8)1 (2.3)3 (3.8)
Time at ESKD (median), yr2.2 (0.9–4.1)1.6 (0.7–2.7)0.101.6 (0.9–2.9)0.13
Unit
 A43 (18.2)13 (30.9)0.0942 (53.2)0.001c
 B192 (81.7)29 (69.0)37 (46.8)
Lymphocyte nadirb (median), 109/L1.2 (0.9–1.6)1.0 (0.8–1.4)0.241.0 (0.7–1.3)<0.001c
CRP peakb (median), mg/L7.5 (2.8–19.4)31.1 (12.4–95.7)<0.001c53.4 (19.3–112.0)<0.001c
Ferritin peakb (median), μg/L404 (298–534)495 (344–597)0.03c817 (529–1532)<0.001c
Immunosuppressed, yes43 (18.3)4 (9.5)0.198 (10.1)0.11
  • APKD, autosomal dominant polycystic kidney disease.

  • a Reference group.

  • b Of all values over the 12-week observation period.

  • c P<0.05.